A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

Running, not enrolling · Phase 3

Conditions studied: Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases

In brief

This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD. The study will determine the short-term and long-term safety and tolerability of L606 in this patient population.

Key facts

Study ID

NCT04691154

Run by

Liquidia Technologies, Inc.

People needed

28

Starts

2021-08-01

Expected to finish

2031-03-31

Last updated by the study team

2026-04-01

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Arizona Pulmonary Specialists — Scottsdale, Arizona, United States
• VA Greater Los Angeles Healthcare — Los Angeles, California, United States
• Mayo Clinic Jacksonville — Jacksonville, Florida, United States
• University of South Florida — Tampa, Florida, United States
• Icahn School of Medicine at Mount Sinai — New York, New York, United States
• University of Cincinnati Medical Center — Cincinnati, Ohio, United States
• Summit Health Eastside Clinic — Bend, Oregon, United States
• Baylor Scott and White Research Institute — Temple, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.